AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2015

May 21, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2015-05-19

Reporting Person: Cantley Lewis Clayton Jr. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-05-19	Common stock	S	2426	$116.69	Disposed	169688	Direct
2015-05-19	Common stock	S	2426	$116.66	Disposed	169688	Indirect
2015-05-20	Common stock	S	2426	$116.60	Disposed	167262	Direct
2015-05-20	Common stock	S	2426	$116.60	Disposed	167262	Indirect

Footnotes

F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $115.00 to $118.92. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: Shares held by Vicki Lee Sato, who is the reporting person's spouse.

F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $116.09 to $117.24. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $116.13 to $117.24. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.